Document is current
Any future updates will be listed below
-
Authors
Gouda, Pishoy
Liu, Yuxi
Butler, Javed
Del Prato, Stefano
Ibrahim, Nasrien E.
Lam, Carolyn S. P.
Marwick, Thomas
Rosenstock, Julio
Tang, Wilson
Zannad, Faiez
Januzzi, James
Ezekowitz, Justin
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04083339 at ClinicalTrials.govDocuments that mention this clinical trial
462-P: AT-001, a Next Generation Aldose Reductase Inhibitor with Improved Selectivity and Specificity, Protects from Cellular Damage Associated with Hyperglycemia
https://doi.org/10.2337/db20-462-p
1080-P: Addressing the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy, a Potent and Selective Next Generation Aldose Reductase Inhibitor
https://doi.org/10.2337/db20-1080-p
Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy
https://doi.org/10.1186/s12933-024-02378-w
186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)
https://doi.org/10.2337/db20-186-or
-
Funding
Funding for this research was provided by:
Applied Therapeutics, Inc.
- License Information
-
More Information
Article History
Received: 8 May 2024
Accepted: 26 July 2024
First Online: 2 August 2024
Declarations
:
: Javed Butler: Consultant—Abbott, American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element Science, Innolife, Impulse Dynamics, Imbria, Inventiva, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Roche, Sequana, SQ Innovation, Tenex, and ViforWilson Tang: Dr. Tang served as consultant for Sequana Medical, Cardiol Therapeutics, Genomics plc, Zehna Therapeutics, Renovacor, WhiteSwell, Kiniksa, Boston Scientific, CardiaTec Biosciences, Intellia Therapeutics, and has received honorarium from Springer, Belvoir Media Group, and American Board of Internal Medicine. Carolyn S.P. Lam: Carolyn SP Lam is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has Received research support from NovoNordisk and Roche Diagnostics; has Served as consultant or on the Advisory Board/ Steering Committee/ Executive Committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, Cytokinetics, Darma Inc., EchoNous Inc, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, Prosciento Inc, Quidel Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics and Us2.ai; and serves as co-founder & non-executive director of Us2.ai.Stefano Del Prato reports serving as president of EASD/EFSD (2020-2022) and has received research grants to the institution from AstraZeneca and Boehringer Ingelheim; has served as advisor for Abbott, Applied Therapeutics, AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., EvaPharma, Jiangsu Hengrui Pharmaceuticals Co., Menarini International, Merck Sharpe & Dohme, Novartis Pharmaceutical Co., Novo Nordisk, Sanofi, Sun Pharmaceuticals; has received fees for speaking from Abbott, AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Eli Lilly & Co., Laboratori Guidotti, Menarini International, Merck Sharpe & Dohme, Novo Nordisk, Sanofi.All other authors declare no conflicts of interest.
